Skip to main content

Sandoz launches new dosage strength of its Copaxone generic

2/13/2018
Sandoz is launching its Glatopa, a generic of Copaxone (glatiramer acetate injection) following approval from the Food and Drug Administration on Tuesday. Glatopa was approved as a fully substitutable Copaxone generic in 40 mg/ml dosage strength. Sandoz launched Glatopa in 20 mg/ml dosage strength in 2015.

The Copaxone generic is indicated to treat relapsing forms of multiple sclerosis, and Sandoz developed Glatopa through a collaboration agreement between itself and Momenta Pharmaceuticals.

“The approval and launch of Glatopa 40 mg/mL reinforces our leadership in delivering complex, differentiated generic products,” Sandoz CEO Richard Francis said. “We look forward to bringing this product to patients and healthcare professionals and providing a full range of patient support services for Glatopa through GlatopaCare.”

Sandoz’s GlatopaCare program offers a $0 co-pay support program for certain patients. The company also offers personalized injection training for patients, as well as a starter kit that includes the Glatopaject injection device that works with Glatopa prefilled syringes, Sandoz said.
X
This ad will auto-close in 10 seconds